J Cancer
2019; 10(19):4596-4602.
doi:10.7150/jca.31184 This issueCite
Research Paper
The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients
Dan Hu1*, Feng Peng2*✉, Xiandong Lin3, Hejun Zhang1, Yan Xia1, Jinxiu Lin2, Xiongwei Zheng1, Wenquan Niu4✉
1. Department of Pathology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China 2. Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China 3. Department of Radiobiology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China 4. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China *Shared first authors.
✉ Corresponding authors: Wenquan Niu, Ph.D. Address: No.2 Yinghua East Street, Chao Yang District, Beijing 100029, China. Tel & Fax: 86-10-8420 6414. E-mail: niuwenquan_shcncom or niuwenquancom.cn. Or Feng Peng, M.D. Ph.D. Address: No.20 Chazhong Road, Tai Jiang District, Fuzhou 350005, Fujian, China. Tel: +86-591-8798 1637. Fax: +86-591-8798 1635. E-mail: pengfengfuzhoucomMore
Citation:
Hu D, Peng F, Lin X, Zhang H, Xia Y, Lin J, Zheng X, Niu W. The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients. J Cancer 2019; 10(19):4596-4602. doi:10.7150/jca.31184. https://www.jcancer.org/v10p4596.htm
Backgrounds: High blood glucose or hyperglycemia is an established risk factor for the development and progression of cancer at many sites, whereas data on the relevance between low blood glucose or hypoglycemia and cancer survival are lacking.
Aims: We aimed to assess the shape of risk trajectory between preoperative fasting glucose and postoperative digestive cancer-specific mortality in Chinese.
Methods: In total, 6865 patients who underwent radical surgery for esophageal cancer (n=2535), gastric cancer (n=3012) and colorectal cancer (n=1318) during 2000-2010 were followed up as of December 2015. All patients received neither chemotherapy nor radiotherapy before and after the surgery. Optimal cutoff points were determined using survival tree analysis.
Results: The median follow-up time was 44.9 months (range: 0.5-188.9 months), with 1065 deaths from esophageal cancer, 1331 from gastric cancer and 412 from colorectal cancer. Using fasting glucose (4.36, 6.09] mmol/L as the reference group, hazard ratios for fasting glucose ≤4.36, (6.09, 8.95], (8.95, 11.5] and >11.5 mmol/L were 1.35 (95% confidence interval: 1.19, 1.54), 2.82 (2.57, 3.11), 3.56 (3.10, 4.08) and 4.27 (3.67, 4.97), respectively (p<0.001).
Conclusions: Our findings indicate a U-shaped risk trajectory between preoperative fasting glucose and digestive tract cancer-specific mortality in Chinese. Further external validation is warranted.
Hu, D., Peng, F., Lin, X., Zhang, H., Xia, Y., Lin, J., Zheng, X., Niu, W. (2019). The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients. Journal of Cancer, 10(19), 4596-4602. https://doi.org/10.7150/jca.31184.
ACS
Hu, D.; Peng, F.; Lin, X.; Zhang, H.; Xia, Y.; Lin, J.; Zheng, X.; Niu, W. The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients. J. Cancer 2019, 10 (19), 4596-4602. DOI: 10.7150/jca.31184.
NLM
Hu D, Peng F, Lin X, Zhang H, Xia Y, Lin J, Zheng X, Niu W. The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients. J Cancer 2019; 10(19):4596-4602. doi:10.7150/jca.31184. https://www.jcancer.org/v10p4596.htm
CSE
Hu D, Peng F, Lin X, Zhang H, Xia Y, Lin J, Zheng X, Niu W. 2019. The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients. J Cancer. 10(19):4596-4602.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.